Novo Nordisk (NVO) stock fell after announcing that CEO Lars Fruergaard Jørgensen will step down. BMO Capital Markets ...

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said ...

Wegovy-maker Novo Nordisk said on Friday its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing ...

It was a ‘mutual agreement,’ Novo says in a statement. A search for Fruergaard Jørgensen’s successor is ongoing.

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

The common theme at the maker of Wegovy and at UnitedHealth may be investors' sudden awareness of cost-cutting pressure.

Helge Lund, chair of the Novo Nordisk Board, expressed confidence in the company’s strategy and its ability to execute ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

CVS Health runs prescription drug coverage ... The study, the first head-to-head comparison of the two, was funded by Lilly. Novo Nordisk’s share price is down 54% from its peak in June 2024.